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Abstract
Background: A truncating variant, 1100delC, in check point-kinase CHEK2, has been identified as
a risk factor for familial and sporadic breast cancer. The prevalence in healthy non-breast cancer
cases is low and varies between populations.
Methods: We analyzed the prevalence of CHEK2 1100delC in 763 breast cancer patients with a
defined family history and 760 controls from the Stockholm region. The breast cancer patients
originated from; a population-based cohort (n = 452) and from a familial cancer clinic (n = 311), the
detailed family history was known in both groups.
Results: The variant was found in 2.9% of the familial cases from the population-based cohort and
in 1.9% from the familial cancer clinic. In total 2.2% of the patients with a family history of breast
cancer carried the variant compared to 0.7% of the controls (p = 0.03). There was no increased
prevalence in sporadic patients (0.3%). The variant was most frequent in young familial patients
(5.1% of cases ≤45 years, p = 0.003). The mean age at diagnosis of variant carriers was 12 years
lower than in non-carriers (p = 0.001).
Conclusion: In conclusion, CHEK2 1100delC exists in the Swedish population. The prevalence is
increased in familial breast cancer and the variant seems to influence age at onset.
Background
Apart from gender, family history is the most important
risk factor for breast cancer. Mutations in the known high-
risk genes BRCA1, BRCA2, p53, ATM and PTEN account
for less than 25% of the familial risk for breast cancer
while the remainder are still genetically unexplained
despite large efforts in research [1]. A polygenic model
with variations in several loci, each contributing a modest
independent risk has been shown to best explain the
residual non BRCA1/2 aggregation of breast cancer, and
the effect of low penetrant genes may also at least partly
explain sporadic breast cancer [2,3]. However, there are
few conclusive results on variants in candidate low-pene-
trant genes even though a large number of case-control
studies, most relatively small in sample size, have been
performed [4]. Association studies on variants conferring
modest risks require large sample sizes; the study size is
however also influenced by the variant frequency. In gen-
eral unselected breast cancer cases are used for association
studies, but the study size can be reduced by selecting
Published: 17 August 2007
BMC Cancer 2007, 7:163 doi:10.1186/1471-2407-7-163
Received: 16 March 2007
Accepted: 17 August 2007
This article is available from: http://www.biomedcentral.com/1471-2407/7/163
© 2007 Margolin et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2007, 7:163 http://www.biomedcentral.com/1471-2407/7/163
Page 2 of 7
(page number not for citation purposes)
cases enriched for genetic susceptibility such as patients
with family history or bilateral cases [5]. A rare truncating
variant in CHEK2 (1100delC), a G2 checkpoint-kinase,
that is involved in cell cycle control and DNA-repair, was
identified as a risk factor for breast cancer in two inde-
pendent studies using this approach [6-8]. The variant fre-
quency was assessed in high-risk familial non BRCA1/2
cases and healthy controls, and both studies were highly
significant despite the fact that the variant is rare (1% or
less in normal population) and confers a relative risk of
around 2 [7,8]. More than 600 unselected cases were
tested in each study but no significant difference in allele
frequency between unselected cases and controls was
detected [7,8]. The variant was suggested to be a low-pen-
etrance gene as described in the polygenic model but the
possibility of a role as a modifier of as – yet unknown
high-risk gene/s has also been proposed [7-9]. A subse-
quent collaboration study of more than 10 000 cases and
controls has demonstrated a doubled risk also in unse-
lected cases carrying the variant [10]. In the present study
we analyse the importance of the variant among breast
cancer patients with a known familial disposition com-
pared to sporadic cases and controls. Furthermore, we
evaluate the significance of the variant as a modifier gene
versus a low-penetrance gene.
Methods
Material
Familial Risk Cohort
311 independent familial cases collected at the Depart-
ment of Clinical Genetics at Karolinska Hospital, Stock-
holm were used for the study. These patients had either
been referred due to a breast cancer diagnosis and a family
history of breast cancer or had been collected as part of
previous research on familial breast cancer [11]. All cases
had proceeded through genetic counseling and almost all
(>90%) had been screened negative for BRCA1/2 muta-
tions (those who met the current criteria for screening and
the majority of the others as part of previous research to
define criteria for screening). BRCA1 and BRCA2 muta-
tions are rare in the Stockholm region and in previous
studies only 1% mutations in each gene were detected in
familial breast cancer if not using age criteria [12,13].
For the Familial Risk cohort only age at diagnosis was
available (missing in 16 patients).
Population-based cohort
Patients with a surgically treated primary invasive breast
cancer admitted to the Department of Oncology at Hud-
dinge Hospital and Söder Hospital (covering the popula-
tion of southern Stockholm of 850 000 people) from
October 1998 to May 2000 were asked participate in a
study on genetic risk factors from breast cancer [14]. Fam-
ily history, age at diagnosis, hormone receptor status and
histology of the tumor were obtained from all cases and
the median follow-up was 5 years. This cohort consists of
489 patients in total and 456 were used in this study due
to logistic reasons. The samples had previously been
screened for mutations in exon 11 of BRCA1 where more
than 70% of the mutations, including four founder muta-
tions, identified in the Stockholm region are found [14].
Four cases with known BRCA1 or BRCA2 mutations were
excluded from the study.
Cases with at least one 1st or 2nd-degree relatives with
breast cancer in addition to the proband, regardless of age,
were classified as familial breast cancer. In the Familial
risk cohort 168 cases had one 1st or 2nd degree relative,
while the remainder had more than one 1st or 2nd degree
relative. In the population-based cohort 104 cases had
one relative and 35 more than one relative with the dis-
ease.
The mean age at diagnosis in the Familial risk cohort was
54 years (24–92 years). In the Population-based cohort
the mean age was 60 years (27–88 years) and there was no
statistically significant difference between familial and
sporadic cases (59 and 61 years respectively).
As controls we used DNA from 760 geographically
matched blood-donors of mixed gender collected as a
control material for association studies at Karolinska Uni-
versity Hospital, Stockholm, Sweden.
The Ethical Committee at the Karolinska Institute
approved the study.
Methods
Genotyping of the most common mutation in the CHEK2
gene (1100delC) was performed on controls and patients
by PCR with a primer set that is specific for the mutation
(M-CHEK2del100C-F: 5'-gca aag aca tga atc tgt aaa gtc-3'
M-CHEK2del100C-R: 5'-aaa tct tgg agt gcc caa aat aat-3'
and a primer set specific for the wild type allele: (W-
CHEK21100delC-F: 5'-gca aag aca tga atc tgt aaa gtc-3' and
3' W-CHEK21100delC-R: 5'-aaa tct tgg agt gcc caa aat cag-
3' resulting in 184 base pair products. DNA amplifications
were carried out in a 20 µl volume containing 1 × Ampli-
qon III standard buffer (Ampliqon ApS, Copenhagen),
125 µM of each dNTP, 4 pmol of each primer, 0.5 units of
Amplicon III Taq Polymerase (Ampliqon ApS, Copenha-
gen), and 25 – 50 ng of template DNA. The PCR condi-
tions were: initial denaturation at 95°C for 5 min.
hereafter 40 cycles at 95°C for 20 sec, 59°C for 20 sec and
72°C for 20 sec followed by 5 min. of extension at 72°C.
The two reactions were run separately each in multiplex
with a control PCR (Control-F: 5'-gtc aaa gcc acc agt tac
agt-3' and Control-R: 5'-ttc ccc acc act tta ctg ac-3') result-BMC Cancer 2007, 7:163 http://www.biomedcentral.com/1471-2407/7/163
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ing in a product of 309 base pairs on chromosome 4. The
products were separated on 2.1% SeaKem LE Agarose
(Cambrex, Bio Science Rockland, Inc., Rockland, ME,
USA) gels. In order to examine for homozygosity for the
variant, PCR for wild type allele and control were per-
formed in cases with the CHEK2 1100CdelC variant.
Statistical analysis
Fisher's exact test was used to compare categorical data.
Continuous data were compared using the two-sample t-
test.
Results
The prevalence of CHEK2  1100delC was 1.9% in the
familial risk Cohort and 1.1% in the population-based
cohort compared to 0.7% in the controls (p = 0.09 and
0.51 respectively). 2.2% of all the familial cases carried the
variant (p = 0.03), corresponding to an odds ratio of 3.4
(95% CI 1.2–10.1). (Table 1). Only one of the sporadic
cases carried the variant (0.3%). There was an increasing
frequency of the variant with decreasing age at diagnosis
in the familial patients (Table 2).
The mean age at diagnosis of variant carriers was 12
(familial risk cohort) and 10 (population-based cohort)
years lower in carriers than in non-carriers; 42 (24–55) vs.
54 years in familial risk cohort (p = 0.01) and 50 years
(38–65) versus 60 years in the population-based cohort
(p = 0.06). If the groups were combined the difference in
mean age at onset was 12 years (46 vs. 58 years, p =
0.001).
In three families of carriers from the Familial Risk cohort,
DNA was available for more family members. In two of
these families, the mutation carrier status did not segre-
gate with disease (Figure 1).
The five heterozygotes in the Population-based cohort all
had unilateral ductal breast cancer without recurrence or
secondary malignancies with 6 years follow-up.
Only one CHEK2 1100delC carrier did not have a family
history of breast cancer (Table 3).
Discussion
We have evaluated the prevalence of the CHEK2
1100delC variant in two cohorts of breast cancer patients
from the Stockholm region, one familial and one popula-
tion-based, both with a well-defined family history and in
controls. In our study CHEK2 1100delC was associated
with familial breast cancer (2.2% vs. 0.7% in controls, p =
0.03) and confirm previous results of the variant as a risk
factor for breast cancer.
In the original studies from Finland and the Netherlands
the prevalence in familial breast cancer was 3.1–5.5 %
[7,8]. The highest prevalence of CHEK2 1100delC has
been reported in familial non-BRCA1/2 families also har-
boring colon cancer cases (18%) and in some highly
selected high-risk breast cancer families (9–11%)
[9,15,16]. The prevalence varies according to ethnicity
and in studies mainly from Central and southern Europe,
the variant, even in high-risk families, is very rare (<1%)
[17-20].
Sporadic breast cancer cases have been reported to have a
higher prevalence of the variant than healthy controls as
demonstrated in the large pooled study by the Breast Can-
cer Consortium (1,9% vs. 0.75%) [10]. In our study, we
found no accumulation of CHEK2 1100delC among spo-
radic cases, the cohort however too small to draw any firm
conclusions. The difference in prevalence in our two
cohorts regarding familial breast cancer (1.9% vs. 2.9%) is
also based on very few cases and we refrain from analyz-
ing this difference.
The prevalence of CHEK2 1100delC in our controls was
0.7%, which is consistent with previous studies in the
Swedish population (0.4–1%) and the large pooled con-
trol material of more than 9000 controls, mainly of West-
ern European origin (0.7%) [10,21-23].
In our material the CHEK2 1100delC carriers were mark-
edly younger at diagnosis compared to non-carriers, even
though the difference was of borderline significance in the
two groups of breast cancer cases and the material small.
Several previous studies support this finding including the
Table 1: Prevalence of CHEK2 1100delC in sporadic and familial breast cancer and controls
CHEK2 1100delC+/total tested p-value1
Familial Risk Cohort 6/311 (1.9%) 0.09
Population-based Cohort 5/452 (1.1%) 0.51
Sporadic breast cancer 1/313 (0.3%) 0.68
Familial Breast Cancer 4/139 (2.9%) 0.04
All Familial patients 10/450 (2.2%) 0.03
Controls 5/760 (0.7%)
1P-values were calculated with Fisher's test for associationBMC Cancer 2007, 7:163 http://www.biomedcentral.com/1471-2407/7/163
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large pooled analysis where mutation prevalence
decreased with increasing age at diagnosis [9,10,15,24-
26]. Other studies have found a modest, non-significant,
difference regarding age at onset and there are also nega-
tive studies including the original Dutch study
[7,8,16,27,28]. In the Dutch study, however, only familial
cases were included and the mean age in both carriers and
non-carriers was 45 years, which was much lower than in
breast cancer patients in general, resulting in decreased
power for identification of differences in age at onset. In a
recent Swedish study on postmenopausal breast cancer
there was 0.7% 1100delC carriers in cases compared to
0.4% in controls, which is consistent with our data on
older patients even with a family history (Table 2) since
the majority of our mutation carriers were diagnosed pre-
menopausally [23].
CHEK2 was originally suggested to be a high-risk gene for
the Li Fraumeni syndrome [29]. There is limited or no co-
segregation of CHEK2 1100delC and disease in families
both in our and other previous studies which contradicts
this role of CHEK2 [7-9,16,30,31]. The role for the
CHEK2 1100delC variant might then either be a low risk
variant on its own, or constitute a modifier of risk in syn-
dromes with as yet unknown high-risk gene(s).
Our results, generated in a material with a well-defined
family history including the paternal side, support the
role of a modifier, as there was no accumulation of the
variant in true sporadic cases, and the variant seemed to
influence the age at diagnosis in carriers. Our material is
however relatively small, and this conclusion would need
to be verified in a larger material.
Conclusion
In conclusion the CHEK2 1100delC variant was signifi-
cantly more frequent in familial cases assumed to modify
an underlying hereditary fault Since the effect of the vari-
ant is modest and the variant rare, there is no need for
CHEK2 1100delC screening at present but the variant
might prove interesting in combination with other
genetic/non-genetic factors in the future.
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Table 3: Family history of the CHEK2 1100delC carriers (dr = degree relative/s)
Family number and age at diagnosis Breast Cancer Other malignancies
102, 65 Five 1st dr including one male, age 40–67 One 1st dr with cancer uteri
195, 54 One 1st dr with brain tumour
510, 41 One 2nd dr
764, 52 One 1st dr, age 28
875, 38 One 1st dr, age 36 One 1st dr with non-Hodgkin lymphoma
One 2nd dr with colon cancer
929, 24 One 1st dr, age 66
One 3rd dr, age 45
One 4th dr, age 59
One 3rd dr with pancreatic cancer, Two 3rd dr 
with cancer of the abdomen
1902, 55 One 2nd dr, age 75 One 1st dr with gyn. malignancy
One 2nd dr with cancer of the abdomen
One 2nd dr with sarcoma
4002, 44 One 1st dr, age 51
Two 2nd dr, age 57, 60
One 3rd dr
4042, 50 Two 1st dr, age 37, 53
One 2nd dr, age 55
One 2nd dr with pancreatic cancer
5031, 46 One 1st dr, age 44
5611, 30 Two 2nd dr, age 58, unknown
One 3rd dr, age 51
One 2nd dr with cancer uteri
Table 2: Prevalence of CHEK2 1100delC in familial breast cancer according to age at diagnosis compared to controls (Familial Risk 
Cohort and Population-based cohort, age at diagnosis missing in 16 patients)
Age at diagnosis, years CHEK2 1100delC+/total tested p-value1
<45 5/98 (5.1%) 0.003
46–55 4/148 (2.7%) 0.04
>55 1/188 (0.5%) 1.0
1P-values were calculated with Fisher's test for associationBMC Cancer 2007, 7:163 http://www.biomedcentral.com/1471-2407/7/163
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Pedigrees of families, arrow = index case Figure 1
Pedigrees of families, arrow = index case. Black symbols are breast cancer cases; gray symbols are cases with any other cancer 
and the number below the symbols are age at diagnosis. WT = CHEK2 1100delC mutation, M = CHEK21100delC carrier.BMC Cancer 2007, 7:163 http://www.biomedcentral.com/1471-2407/7/163
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